Young Nancy A, Moriarty Ann T, Walsh Molly K, Wang Edward, Wilbur David C
Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pa 19111, USA.
Arch Pathol Lab Med. 2006 Aug;130(8):1114-8. doi: 10.5858/2006-130-1114-TPFFIG.
Current regulatory proficiency testing scoring results in an automatic failure for identifying high-grade squamous intraepithelial lesion (HSIL) as negative.
The College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology data from January 2004 to April 2005 were analyzed to estimate the percentage of failure based on negative responses for HSIL and validation criteria.
More than 15,000 participants received field-validated and educational slide sets for conventional, ThinPrep, and SurePath modules. Educational sets fulfilled the validation criteria of the Center for Medicare and Medicaid Services, which required the consensus diagnosis of biopsy-proven HSIL (not field-validated) after review by 3 pathologists. The College of American Pathologists field validation required at least 20 responses to the HSIL+ series, with 70% matched to HSIL+ (standard error < or = 0.05). Minimum regulatory proficiency testing failure estimates were based on incorrect negative responses for the reference category of HSIL.
For both cytotechnologists and pathologists, there was a statistically significant higher failure rate for slides that were not field-validated versus those that were field-validated. In conventional modules, 5.3% of the slides that were not field-validated were called negative, versus 1.2% of the field-validated slides. In all liquid-based preparations, 4.0% of the non-field-validated versus 2.2% field-validated slides were called negative. Pathologists would have failed more often than cytotechnologists for the slides that were not field-validated, whereas there was no statistical difference in failure performance with field-validated slides.
Failures were significantly greater with the slides that were not field-validated for both conventional and liquid-based preparations (ThinPrep only) and have implications for both regulatory proficiency testing and expert legal review. Poor performance of pathologists relative to that of cytotechnologists may reflect a lack of prescreening of slides or scope of practice issues.
当前的监管能力验证测试评分结果会导致将高级别鳞状上皮内病变(HSIL)鉴定为阴性时自动判定为不合格。
分析美国病理学家学会2004年1月至2005年4月宫颈阴道细胞学实验室间比较项目的数据,以根据HSIL的阴性反应和验证标准估计不合格率。
超过15000名参与者收到了针对传统、ThinPrep和SurePath模块的现场验证和教育玻片集。教育玻片集符合医疗保险和医疗补助服务中心的验证标准,该标准要求在3名病理学家审查后对活检证实的HSIL(未进行现场验证)达成共识诊断。美国病理学家学会的现场验证要求对HSIL+系列至少有20份反应,其中70%与HSIL+匹配(标准误差≤0.05)。最低监管能力验证测试不合格估计数基于HSIL参考类别中的错误阴性反应。
对于细胞技术人员和病理学家而言,未进行现场验证的玻片的不合格率在统计学上显著高于进行了现场验证的玻片。在传统模块中,未进行现场验证的玻片中5.3%被判定为阴性,而进行了现场验证的玻片中这一比例为1.2%。在所有液基制片中,未进行现场验证的玻片中4.0%被判定为阴性,而进行了现场验证的玻片中这一比例为2.2%。对于未进行现场验证的玻片,病理学家比细胞技术人员更容易判定为不合格,而对于进行了现场验证的玻片,两者在不合格表现上没有统计学差异。
对于传统制片和液基制片(仅ThinPrep)中未进行现场验证的玻片,不合格情况明显更多,这对监管能力验证测试和专家法律审查都有影响。病理学家相对于细胞技术人员表现不佳可能反映出玻片预筛查不足或执业范围问题。